The new list was announced and made official on 29/06/09. The Russell indexes are widely used by investment managers and institutionals for index funds and as benchmarks for both passive and active investment strategies. It is estimated that $4 trillion in assets are currently benchmarked to Russell indexes.
The following healthcare sector companies will bring value to their shareholders and expose their stocks to a broader base of institutional investors. A complete list of all healthcare stocks whish were added and deleted can be found on BioMedReports.Com
Insmed Incorporated(NASDAQ:INSM) - Insmed Incorporated (Insmed) is a development stage biopharmaceutical company specializing in recombinant protein drug development. The Company also engaged the services of RBC to act as financial advisor. On March 31, 2009, the Company completed the sale of its follow-on biologics assets to Merck & Co., Inc. (Merck).
Lannett Company, Inc.(AMEX:LCI) - Lannett Company, Inc. (Lannett) develops, manufactures, markets and distributes generic versions of pharmaceutical products. The Company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private-label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups and health maintenance organizations. As of June 30, 2007, Lannett manufactured and/or distributed 28 products. All of the products are manufactured and/or sold by the Company are prescription products. Of the products, those containing Butalbital, Digoxin, Primidone and Levothyroxine Sodium were the Company's key products, contributing 76% of the Company's total net sales during the fiscal year ended June 30, 2008 (fiscal 2008). Lannett has two products containing butalbital.
Medifast, Inc.( NYSE:MED) - Medifast, Inc. (Medifast) is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. The Company's product lines include weight and disease management, meal replacement, and vitamins primarily manufactured in its modern, the United States Food and Drug Administration (FDA) approved facility in Owings Mills, Maryland. The Company's operations are primarily conducted through five of its wholly owned subsidiaries, Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSF), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. The Company offers a variety of weight and disease management products under the Medifast brand and for select private label customers. It's distribution channels include Medifast Direct, Take Shape for Life, Medifast Weight Control Centers and Medifast Physicians.
Merge Healthcare Inc.(NASDAQ:MRGE) - Merge Healthcare Incorporated (Merge) develops medical imaging and information software solutions and delivers related services. The Company's solutions are designed to automate digital imaging workflow, which transforms the tasks associated with film-based images and paper information into computerized processes. It sells these solutions through two business units: Merge Fusion and Merge OEM. Merge Fusion sells directly to hospitals, imaging centers and specialty clinics located in the United States, sells directly and through distributors outside the United States, and also distributes certain products through the Internet via its Website. The Company's Merge OEM business unit primarily sells to original equipment manufacturers (OEMs), value added resellers (VARs) and distributors located globally.
Investors are invited to view the entire list of additiond and deletions at:
http://biomedreports.com/articles/most-popular/1717-big-list-of-healthcare-stocks-crack-russell-3000.html
Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here: http://biomedreports.com/fda-calendar/fda-calendar.html
Disclosure: No positions.
About BiomedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.
For more biomedical sector and investment news, go to www.BioMedReports.com
Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.
All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.
CONTACT: Mike Havrilla, Managing Editor, BiomedReports.Com e-mail: mike@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index